PT 141 Bremelanotide CAS 189691-06-3
DISODIUM DIHYDROGEN DIPHOSPHATE CAS 7758-16-9
2 7 月, 2020Cadmium chloride CAS 10108-64-2
2 7 月, 2020
REMELANOTIDE Typical Properties
| Product Name: | PT-141 |
| Synonyms: | Bremelanotide;PT141 Acetate,BreMelanotide Acetate;Ac-Nle-cyclo(-Asp-His-D-Phe-Arg-Trp-Lys);Bremelanotide,α-MSH (PT-141);BREMELANOTIDE;Brmelanotice;Ac-Nle-cyclo(-Asp-His-D-Phe-Arg-Trp-Lys)-OH;Bremelanotide, PT141,PT-141 |
| CAS: | 189691-06-3 |
| MF: | C50H68N14O10 |
| MW: | 1025.18 |
| Product Categories: | Peptides |
| Mol File: | 189691-06-3.mol |
| density | 1.43 |
| pka | 3.37±0.70(Predicted) |
Bremelanotide Usage
Absrtact Bremelanotide (formerly PT-141) is a compound under drug development by Palatin Technologies as a treatment for female sexual dysfunction, hemorrhagic shock and reperfusion injury.
It functions by activating the melanocortin receptors MC1R and MC4R, to modulate inflammation and limitingischemia.
It was originally tested for intranasal administration in treating female sexual dysfunctionbut this application was temporarily discontinued in 2008 after concerns were raised over adverse side effects of increased blood pressure. As of March, 2012, Palatin is conducting a human Phase 2B study using a new subcutaneous drug delivery system that appears to have little effect on blood pressure.
Bremelanotide Packaging and Shipping
Packaging:1kg/drum, as customer’s request
Shipping:It can be according to the customer’s request